

---

 DIGEST

The digest printed below was prepared by House Legislative Services. It constitutes no part of the legislative instrument. The keyword, one-liner, abstract, and digest do not constitute part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]

---

SB 43 Reengrossed

2026 Regular Session

McMath

Proposed law establishes the Psychedelic-Assisted Therapy Initiative within the La. Dept. of Health, office of behavioral health.

Proposed law establishes the following purposes of the initiative:

- (1) To identify academic health centers that are conducting clinical studies and clinical trial-enabling studies for the use of psychedelic-assisted therapy for the treatment of opioid use disorders, co-occurring substance use disorders, and treatment-resistant neurological or mental health conditions.
- (2) To utilize the human service districts and authorities to identify eligible participants.
- (3) To provide information to allow parishes utilizing opioid settlement funds to enroll eligible patients residing in the parish to participate in the studies or to support clinical trial-enabling studies.

Proposed law authorizes the department to seek and receive federal funds, gifts, grants, and donations for the program in addition to utilizing opioid settlement funds.

Proposed law requires participating academic health centers to submit an annual progress report to the department and requires the department to submit a compiled report to the legislature by March first of each year.

Proposed law requires the participating academic health centers to coordinate with other states that are conducting clinical trials for the use of psychedelic-assisted therapy to the extent feasible.

Proposed law authorizes academic health centers to enter into agreements with drug developers to establish a consortium for purposes of conducting drug development clinical trials with ibogaine and provides for the process to establish a consortium.

Proposed law provides for the distribution of any revenue attributable to intellectual property rights and other commercial rights arising from a drug development clinical trial.

Effective August 1, 2026.

(Adds R.S. 28:211 and 212)

Summary of Amendments Adopted by Senate

Committee Amendments Proposed by Senate Committee on Health and Welfare to the original bill

1. Changes requirements relative to the La. Dept. of Health's role in overseeing the clinical trials.
2. Changes requirements relative to required documentation for academic health centers conducting trials.
3. Authorizes academic health centers to enter into agreements with drug developers to conduct ibogaine clinical trials and participate in a consortium with other states.

Senate Floor Amendments to engrossed bill

1. Changes the Psychedelic-Assisted Therapy Program to an initiative within the La. Dept. of Health.
2. Moves certain program requirements from the La. Dept. of Health to the human service districts and authorities and the academic health centers.
3. Changes certain clinical study requirements for participating academic health centers.
4. Changes the submission date of the La Dept. of Health's report to the legislature.

Summary of Amendments Adopted by House

The Committee Amendments Proposed by House Committee on Health and Welfare to the reengrossed bill:

1. Make technical changes.